Recruiting studies: Mek Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1 · 1 location(s) · China Medical University Hospital · NCT06962254 PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565 Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Phase 2 · 1 location(s) · N.N. Petrov National Medical Research Center of Oncology · NCT06229340 A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK
Phase N/A · 1 location(s) · Mandana Kamgar, MD · NCT05630989 Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Phase 1 · 4 location(s) · Rina Plattner · NCT04903119 A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Phase 1 · 23 location(s) · Nested Therapeutics, Inc · NCT06326411 PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839 A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 2 · 2 location(s) · Murdoch Childrens Research Institute · NCT05983159

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.